Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
01/06/2022 - 07:00 AM
CHICAGO --(BUSINESS WIRE)--
Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick , Chairman and Chief Executive Officer of Xeris Biopharma , will present an overview of the company and highlight recent events, including the FDA approval of Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual conference being held January 10-13, 2022 .
The on-demand presentation will be available beginning January 10, 2022 at 7:00 a.m. E.T. through the investors section on the Company's website at www.xerispharma.com .
About Xeris Biopharma
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has two commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis. In addition, Recorlev® was recently approved by the U.S. Food and Drug Administration for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com , or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220106005180/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma
Xeris Biopharma Holdings Inc
XERS Rankings
#1957 Ranked by Stock Gains
XERS Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About XERS
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.